MDT-AP-0396
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- overall_survival_months
- 54
- os_event
- false
- age_years
- 7
- sex
- F
- new_clusters
- C3
- umap1_2d
- 5.811716895
- umap2_2d
- 2.790297402
- umap1_3d
- 2.594515501
- umap2_3d
- -3.069251139
- umap3_3d
- -2.366522523
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- WNT_BETA_CATENIN_SIGNALING+0.260
- MYC_TARGETS_V2+0.230
- MITOTIC_SPINDLE+0.180
- SPERMATOGENESIS+0.130
- KRAS_SIGNALING_DN+0.100
- G2M_CHECKPOINT+0.050
- UNFOLDED_PROTEIN_RESPONSE+0.050
- HEME_METABOLISM+0.020
- GLYCOLYSIS-0.010
- HEDGEHOG_SIGNALING-0.010
Top 10 suppressed
- TNFA_SIGNALING_VIA_NFKB-0.450
- ALLOGRAFT_REJECTION-0.430
- INFLAMMATORY_RESPONSE-0.430
- INTERFERON_GAMMA_RESPONSE-0.420
- INTERFERON_ALPHA_RESPONSE-0.410
- COMPLEMENT-0.400
- OXIDATIVE_PHOSPHORYLATION-0.360
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.350
- ANDROGEN_RESPONSE-0.310
- P53_PATHWAY-0.310
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MDT-AP-1138 | Med | Medulloblastoma | 0.902 |
| 2 | a50c02ec-6ba9-4678-990d-6c74a8e9b7b5 | — | — | 0.899 |
| 3 | SRR12202412 | — | — | 0.893 |
| 4 | SRR1313141 | — | E | 0.884 |
| 5 | SRR6013546 | — | cohortA1 | 0.883 |
| 6 | SRR604146 | GTEX | — | 0.881 |
| 7 | BS_4W68NV3M | medulloblastoma | — | 0.877 |
| 8 | b3c0ffda-f298-45dd-b494-191788cb7013 | — | — | 0.875 |
| 9 | SRR1324452 | GTEX | — | 0.873 |
| 10 | SRR1364800 | GTEX | — | 0.870 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 8 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| WNT_BETA_CATENIN_SIGNALING | 0.260 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.230 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.180 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.130 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.100 | Remibrutinib | — uncovered |
| G2M_CHECKPOINT | 0.050 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.050 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.020 | Temsirolimus | — uncovered |